Precision BioSciences

DTIL · NASDAQ

$6.56+$0.37 (+5.98%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.19

Latest news

Press releaseOct 8, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Press releaseAug 27, 8:00 AM ETBusiness Wire
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026
NewsAug 25, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseAug 24, 6:01 AM ETBusiness Wire
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Press releaseAug 20, 8:00 AM ETBusiness Wire
iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
Press releaseAug 6, 7:01 AM ETBusiness Wire
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 31, 7:01 AM ETBusiness Wire
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Press releaseJul 27, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Press releaseJul 10, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 29, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
NewsMay 27, 8:31 AM ETNabaparna Bhattacharya
Why Is Precision BioSciences Stock Gaining Wednesday?
Press releaseMay 27, 2:30 AM ETBusiness Wire
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
NewsMay 21, 7:11 AM ET
Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial
Press releaseMay 21, 7:01 AM ETBusiness Wire
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Press releaseMay 18, 8:00 AM ETBusiness Wire
iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial
Press releaseMay 14, 7:01 AM ETBusiness Wire
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Press releaseMay 13, 6:00 AM ETBusiness Wire
iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseMay 5, 7:01 AM ETBusiness Wire
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Press releaseApr 30, 7:01 AM ETBusiness Wire
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Press releaseApr 29, 7:01 AM ETBusiness Wire
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Press releaseApr 28, 8:02 AM ETBusiness Wire
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
Press releaseApr 28, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Press releaseApr 24, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseApr 22, 7:01 AM ETBusiness Wire
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Press releaseApr 15, 7:01 AM ETBusiness Wire
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Press releaseApr 8, 7:01 AM ETBusiness Wire
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Press releaseMar 18, 8:00 AM ETBusiness Wire
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
NewsMar 12, 7:11 AM ET
Earnings Scheduled For March 12, 2026
Press releaseMar 12, 7:00 AM ETBusiness Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
NewsNov 3, 6:11 AM ET
Earnings Scheduled For November 3, 2025
NewsAug 7, 7:03 AM ET
Precision BioSciences Q2 EPS $(2.13) Misses $(1.57) Estimate, Sales $18.00K Miss $6.27M Estimate
NewsAug 7, 4:33 AM ET
Earnings Scheduled For August 7, 2025
NewsJun 25, 7:17 AM ET
Market-Moving News for June 25th
NewsMay 15, 4:32 AM ET
Earnings Scheduled For May 15, 2025
NewsMay 14, 12:05 PM ET
Uncovering Potential: Precision BioSciences's Earnings Preview
NewsMar 26, 4:32 AM ET
Earnings Scheduled For March 26, 2025
NewsMar 19, 2:00 PM ET
Assessing Precision BioSciences: Insights From 4 Financial Analysts

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

Why Is Precision BioSciences Stock Gaining Wednesday?

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Precision BioSciences Announces Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting

Earnings Scheduled For May 5, 2026

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission

Earnings Scheduled For March 12, 2026

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 3, 2025

Precision BioSciences Q2 EPS $(2.13) Misses $(1.57) Estimate, Sales $18.00K Miss $6.27M Estimate

Earnings Scheduled For August 7, 2025

Market-Moving News for June 25th

Earnings Scheduled For May 15, 2025

Uncovering Potential: Precision BioSciences's Earnings Preview

Earnings Scheduled For March 26, 2025

Assessing Precision BioSciences: Insights From 4 Financial Analysts